Novobiocin inhibits passive chromatin assembly in vitro.
Novobiocin, an inhibitor of prokaryotic DNA gyrase and eukaryotic type II topoisomerase enzymes, interferes with in vitro chromatin assembly using purified histones, DNA and nucleoplasmin. The target of inhibition is not topoisomerase II; this energy-independent assembly system lacks any ATP and Mg2+-dependent type II topoisomerase or gyrase activities. Rather, novobiocin interacts with histones, disrupting histone-histone associations required for octamer formation, and causing histones to precipitate from both nucleoplasmin-histone and histone-DNA complexes. Thus, novobiocin is able to generate 'dynamic' chromatin in vitro in the absence of ATP and Mg2+ by removing histones from previously assembled static chromatin, so that the DNA supercoils, previously constrained by conventional nucleosomes, become susceptible to removal by topoisomerase I.
D000818:Animals; D002843:Chromatin / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure*; D004247:DNA / Q000187:drug effects / Q000378:metabolism; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D005260:Female; D006657:Histones / Q000378:metabolism; D009675:Novobiocin / Q000494:pharmacology*; D009687:Nuclear Proteins; D056489:Nucleoplasmins; D009698:Nucleoproteins / Q000378:metabolism; D010063:Ovum / Q000648:ultrastructure; D010750:Phosphoproteins; D014981:Xenopus
D002843:Chromatin; D006657:Histones; D009687:Nuclear Proteins; D056489:Nucleoplasmins; D009698:Nucleoproteins; D010750:Phosphoproteins; D009675:Novobiocin; D004247:DNA; D004264:DNA Topoisomerases, Type I